Deal watch

![]() |
Click here to enlarge |
Deal particulars: Daiichi Sankyo, Japan’s second- largest pharma company, has agreed to acquire a majority stake in Ranbaxy Laboratories for $3.4-4.6 billion (Rs 14,620-19,804 crore). Under the deal, Daiichi will acquire the entire 35 per cent stake of the promoter family, increase its stake by 14 per cent through a preferential offer and launch an open offer for a minimum 20 per cent stake. The deal is expected to be completed by March 2009.
Impact analysis: The deal, the largest for a listed company in India, is a win-win one for both companies. While Ranbaxy has a strong presence in the generics segment in emerging countries, Daiichi has its strengths in new drugs in the advanced markets and together, the companies will have a presence across 56 countries.